These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7695281)

  • 1. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
    WaKabongo M; Stucki ZN; Torbert DP; Olweny J
    J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1499-504. PubMed ID: 7492093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS; Weber DA; Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Turgeon F
    Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests.
    Johnson DM; Doern GV; Haugen TA; Hindler J; Washington JA; Jones RN
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):137-41. PubMed ID: 8902410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
    Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.
    Visalli MA; Jacobs MR; Moore TD; Renzi FA; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):767-70. PubMed ID: 9087486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
    Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.